-
Revenue: US$13.4m (up 152% from 2Q 2024).
-
Net income: US$5.89m (up 97% from 2Q 2024).
-
Profit margin: 44% (down from 56% in 2Q 2024).
-
EPS: US$0.23 (up from US$0.12 in 2Q 2024).
We’ve found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Revenue exceeded analyst estimates by 2.2%. Earnings per share (EPS) also surpassed analyst estimates by 36%.
Looking ahead, revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada.
Performance of the Canadian Pharmaceuticals industry.
The company’s shares are up 27% from a week ago.
You should always think about risks. Case in point, we’ve spotted 2 warning signs for Cipher Pharmaceuticals you should be aware of, and 1 of them can’t be ignored.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.